Spyre Therapeutics, INC Form 4 insider transactions

Jeffrey W. Albers, a Director of Spyre Therapeutics, Inc., sold 23,000 shares of common stock on August 7, 2026.

Scott L Burrows, Chief Financial Officer of Spyre Therapeutics, Inc., sold 7,500 shares of common stock on August 3, 2026.

Cameron Turtle, Chief Executive Officer and a Director of Spyre Therapeutics, Inc., sold 15,000 shares of common stock on August 3, 2026.

Spyre Therapeutics' Chief Financial Officer, Scott L. Burrows, executed a series of stock transactions under a pre-arranged Rule 10b5-1 trading plan.

Sloan Sheldon, Chief Medical Officer of Spyre Therapeutics, Inc., reported transactions involving the sale of common stock and the acquisition of stock options under a Rule 10b5-1 trading plan.

Spyre Therapeutics CEO Cameron Turtle has sold a significant number of company shares through a pre-arranged trading plan.

Spyre Therapeutics, Inc. CFO Scott L. Burrows reports transactions involving common stock and stock options.

Fairmount Funds Management LLC and its affiliates reported the conversion of Series B Preferred Stock into common stock, alongside a sale of common stock.

Director Michael Henderson reported a transaction involving 20,000 shares of Spyre Therapeutics, Inc. common stock on June 22, 2026, executed under a Rule 10b5-1 trading plan.

Chief Medical Officer Sheldon Sloan exercised options and sold 8,333 shares of Spyre Therapeutics at $75.00 per share under a pre-arranged trading plan.

Chief Executive Officer Cameron Turtle sold 15,000 shares of Spyre Therapeutics as part of a pre-arranged trading plan while maintaining a substantial equity position.

Spyre Therapeutics CFO Scott L. Burrows exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Fairmount Funds Management's Tomas Kiselak was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of his board service.

Director Jeffrey W. Albers was granted 8,026 stock options in Spyre Therapeutics, Inc. as disclosed in a recent SEC Form 4 filing.

Director Michael Thomas Henderson was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of standard equity compensation.

Director Laurie Stelzer was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Mark C. McKenna was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of standard equity compensation.

Director Sandra Milligan was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of standard equity compensation.

Director Michael Thomas Henderson sold 80,000 shares of Spyre Therapeutics, Inc. on May 8, 2026, as part of a pre-arranged trading plan.

Spyre Therapeutics Chief Financial Officer Scott L. Burrows exercised options and sold 12,500 shares of common stock as part of a pre-arranged trading plan.

Chief Medical Officer Sheldon Sloan exercised options and sold 78,333 shares of Spyre Therapeutics under a pre-arranged trading plan.

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics CEO Cameron Turtle sold company stock valued at approximately $607,000 through a pre-arranged trading plan.

Spyre Therapeutics, Inc. reports that Chief Medical Officer Sheldon Sloan sold 7,958 shares of common stock on April 1, 2026, as part of a pre-arranged 10b5-1 trading plan.

Spyre Therapeutics, Inc. (SYRE) Chief Financial Officer, Scott L. Burrows, executed a series of stock transactions on April 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics' CFO, Scott L. Burrows, exercised stock options and subsequently sold a portion of the acquired common stock on March 3, 2026, under a pre-arranged 10b5-1 trading plan.

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock for approximately $632,866 through a pre-arranged 10b5-1 trading plan.

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock on February 2, 2026, as part of a pre-arranged 10b5-1 trading plan.

Spyre Therapeutics Director Michael Thomas Henderson acquired 63,227 shares of common stock through a pro-rata distribution from an LLC, increasing his beneficial ownership to 168,606 shares.

Spyre Therapeutics' CFO, Scott L. Burrows, was granted 140,000 stock options with an exercise price of $30.61, vesting over four years.